Anna-Greta Nylander
Overview
Explore the profile of Anna-Greta Nylander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crespo-Facorro B, Such P, Nylander A, Madera J, Resemann H, Worthington E, et al.
Curr Med Res Opin
. 2020 Oct;
37(1):109-121.
PMID: 33095689
Background: Schizophrenia is a heterogeneous disorder with a burden that can vary greatly depending on the severity and the duration. Previous research has suggested that patients in the earlier stages...
2.
Patel M, Bent-Ennakhil N, Sapin C, di Nicola S, Loze J, Nylander A, et al.
BMC Psychiatry
. 2020 Mar;
20(1):123.
PMID: 32169077
Background: Prescription rates for long-acting injectable (LAI) antipsychotic formulations remain relatively low in Europe despite improved adherence over alternative oral antipsychotic treatments. This apparent under-prescription of LAI antipsychotics may have...
3.
Newton R, Rouleau A, Nylander A, Loze J, Resemann H, Steeves S, et al.
NPJ Schizophr
. 2018 Oct;
4(1):21.
PMID: 30323274
Schizophrenia is a debilitating psychiatric disorder and patients experience significant comorbidity, especially cognitive and psychosocial deficits, already at the onset of disease. Previous research suggests that treatment during the earlier...
4.
Llorca P, Bobes J, Fleischhacker W, Heres S, Moore N, Bent-Ennakhil N, et al.
Eur Psychiatry
. 2018 May;
52:85-94.
PMID: 29734130
Background: The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-interventional study across several European countries examining prescription of long-acting injectable (LAI) antipsychotics to identify sociodemographic and clinical characteristics...
5.
Bridges J, Beusterien K, Heres S, Such P, Sanchez-Covisa J, Nylander A, et al.
Patient Prefer Adherence
. 2018 Jan;
12:63-70.
PMID: 29379273
Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18-35 years with a confirmed...
6.
Beusterien K, Chan E, Such P, de Jong Laird A, Heres S, Amos K, et al.
Curr Med Res Opin
. 2017 Sep;
33(12):2129-2136.
PMID: 28945106
Objective: This study sought to evaluate a new stated-preference instrument to prioritize multiple treatment goals among people with recent onset schizophrenia. Methods: A draft survey instrument was developed to assess...
7.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
PLoS One
. 2017 Aug;
12(8):e0183475.
PMID: 28837593
Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between...
8.
Naber D, Baker R, Eramo A, Forray C, Hansen K, Sapin C, et al.
Schizophr Res
. 2017 Apr;
192:205-210.
PMID: 28433498
Objective: To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400mg (AOM 400) in patients with schizophrenia. Methods: Patients who completed the QUALIFY study (NCT01795547) in the...
9.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
Int Clin Psychopharmacol
. 2017 Mar;
32(3):147-154.
PMID: 28252452
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM...
10.
Raoufinia A, Peters-Strickland T, Nylander A, Baker R, Eramo A, Jin N, et al.
Int J Neuropsychopharmacol
. 2017 Feb;
20(4):295-304.
PMID: 28204607
Background: Two open-label, randomized, parallel-arm studies compared pharmacokinetics, safety, and tolerability of aripiprazole once-monthly 400 mg following deltoid vs gluteal injection in patients with schizophrenia. Methods: In the single-dose study,...